« Return to News | Study Conduct

NW Bio opens 30 trial sites ahead of schedule

Monday, February 27, 2012 09:50 AM

Northwest Biotherapeutics (NW Bio) now has 30 clinical trial sites open and recruiting across the U.S. in its ongoing phase II clinical trial of DCVaxR-L immune therapy for Glioblastoma multiforme (GBM), the most lethal form of brain cancer. 

NW Bio has reached this milestone ahead of schedule, as the company had projected to reach it by the end of the first quarter. NW Bio also exceeded its projections in the second, their and fourth quarters of 2011.

The company plans to continue adding clinical trial sites and expects to have at least 40 sites open and enrolling by the end of June.  NW Bio will also continue pursuing its programs in Europe. 

“Together with our recently announced partnership with the American Red Cross, the ongoing expansion of our clinical trial sites is helping to build a broad network to bring DCVax to patients throughout the country,” said Linda Powers, CEO of NW Bio. “We are pleased to see the continuing expansion of interest in DCVax in the medical community.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.